Latest Non Small Cell Lung Cancer News

Page 4 of 4
Immutep’s novel immunotherapy combination with radiotherapy and KEYTRUDA® has met its primary endpoint in a Phase II trial for resectable soft tissue sarcoma, showing promising early signs of improved patient outcomes.
Ada Torres
Ada Torres
26 May 2025
Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows a 60.8% response rate in first-line non-small cell lung cancer, outperforming historical benchmarks especially in patients with low PD-L1 expression.
Ada Torres
Ada Torres
15 May 2025
Radiopharm Theranostics has secured Data Safety and Monitoring Committee approval to escalate dosing in its Phase 1 trial of 177Lu-RAD204, expanding patient cohorts across multiple cancer types.
Ada Torres
Ada Torres
12 May 2025
Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.
Ada Torres
Ada Torres
5 May 2025
Immutep Limited has dosed the first patient in its pivotal Phase III lung cancer trial and completed enrolments in multiple studies, supported by a robust cash position expected to fund operations through 2026.
Ada Torres
Ada Torres
29 Apr 2025
Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.
Ada Torres
Ada Torres
31 Jan 2025
Radiopharm Theranostics has secured key ethics approvals to expand its clinical trial portfolio, completed significant preclinical milestones, and raised A$8 million through a strategic placement, while maintaining its cash runway to mid-2026.
Ada Torres
Ada Torres
30 Jan 2025